Brian Humbarger, our new Chief Commercial Officer, will provide an overview of our limited commercial launch. Before we dive into updates since our last call in November, I want to remind everyone ...

HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can ...

HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial ...

DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either 12-lead or single-lead electrocardiogram (ECG) data, has been developed. This ...

Myocardial ischemia, the primary driver of heart attacks, remains the leading cause of death and disability worldwide. Delays in diagnosis directly correlate with increased myocardial necrosis, higher ...

(RTTNews) - HeartBeam, Inc. (BEAT), a medical technology company, announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking ...